Most actionable first. Assess the next decision, not the size of the database.
877 matching trial–asset observations. These are not unique or cleared acquisitions. 0 have all four gates supported in this view; entered assessments still require review.
WATCH · TERMINATED
Schizophrenia
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN
SOURCE FACT The decision to stop the trial was based on efficacy results in the overall schizophrenia participant population.
Rescueability · inferenceUNKNOWN
Current controlUNKNOWN
Next truth · USD / monthsUNKNOWN / UNKNOWN
Restart · inferenceUNKNOWN
Why this survived: Source-backed stopping context warrants a review, not qualification.
Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.
Principal risk: Transferable rights and decision-quality human evidence remain unresolved.
Investigate opportunitySource, stopping context and uncertainty
The decision to stop the trial was based on efficacy results in the overall schizophrenia participant population.
Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established
Acquisition range: UNKNOWN · Market Pull: UNKNOWN
Confidence UNKNOWN. Source update 2026-09-14. Registry source
WATCH · WITHDRAWN
Hepatocellular Carcinoma
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN
SOURCE FACT The study was withdrawn because the pharmaceutical company decided not to pursue this combination of drugs following negative data in another indication.
Rescueability · inferenceUNKNOWN
Current controlUNKNOWN
Next truth · USD / monthsUNKNOWN / UNKNOWN
Restart · inferenceUNKNOWN
Why this survived: Source-backed stopping context warrants a review, not qualification.
Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.
Principal risk: Transferable rights and decision-quality human evidence remain unresolved.
Investigate opportunitySource, stopping context and uncertainty
The study was withdrawn because the pharmaceutical company decided not to pursue this combination of drugs following negative data in another indication.
Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established
Acquisition range: UNKNOWN · Market Pull: UNKNOWN
Confidence UNKNOWN. Source update 2026-09-14. Registry source
WATCH · WITHDRAWN
Hepatocellular Carcinoma
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN
SOURCE FACT The study was withdrawn because the pharmaceutical company decided not to pursue this combination of drugs following negative data in another indication.
Rescueability · inferenceUNKNOWN
Current controlUNKNOWN
Next truth · USD / monthsUNKNOWN / UNKNOWN
Restart · inferenceUNKNOWN
Why this survived: Source-backed stopping context warrants a review, not qualification.
Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.
Principal risk: Transferable rights and decision-quality human evidence remain unresolved.
Investigate opportunitySource, stopping context and uncertainty
The study was withdrawn because the pharmaceutical company decided not to pursue this combination of drugs following negative data in another indication.
Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established
Acquisition range: UNKNOWN · Market Pull: UNKNOWN
Confidence UNKNOWN. Source update 2026-09-14. Registry source
WATCH · TERMINATED
Pain
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN
SOURCE FACT UNKNOWN
Rescueability · inferenceUNKNOWN
Current controlUNKNOWN
Next truth · USD / monthsUNKNOWN / UNKNOWN
Restart · inferenceUNKNOWN
Why this survived: Source-backed stopping context warrants a review, not qualification.
Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.
Principal risk: Transferable rights and decision-quality human evidence remain unresolved.
Investigate opportunitySource, stopping context and uncertainty
UNKNOWN
Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established
Acquisition range: UNKNOWN · Market Pull: UNKNOWN
Confidence UNKNOWN. Source update 2006-11-14. Registry source
WATCH · TERMINATED
Asthma, Chronic Obstructive Pulmonary Disease
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN
SOURCE FACT Sponsor business decision
Rescueability · inferenceUNKNOWN
Current controlUNKNOWN
Next truth · USD / monthsUNKNOWN / UNKNOWN
Restart · inferenceUNKNOWN
Why this survived: Source-backed stopping context warrants a review, not qualification.
Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.
Principal risk: Transferable rights and decision-quality human evidence remain unresolved.
Investigate opportunitySource, stopping context and uncertainty
Sponsor business decision
Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established
Acquisition range: UNKNOWN · Market Pull: UNKNOWN
Confidence UNKNOWN. Source update 2026-09-14. Registry source
WATCH · TERMINATED
Breast Neoplasms, Neoplasms, Hormone-Dependent
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN
SOURCE FACT Identical study Biomed 777-CLP-029 did not meet superiority endpoint
Rescueability · inferenceUNKNOWN
Current controlUNKNOWN
Next truth · USD / monthsUNKNOWN / UNKNOWN
Restart · inferenceUNKNOWN
Why this survived: Source-backed stopping context warrants a review, not qualification.
Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.
Principal risk: Transferable rights and decision-quality human evidence remain unresolved.
Investigate opportunitySource, stopping context and uncertainty
Identical study Biomed 777-CLP-029 did not meet superiority endpoint
Why stranded: Endpoint failure · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established
Acquisition range: UNKNOWN · Market Pull: UNKNOWN
Confidence UNKNOWN. Source update 2007-08-23. Registry source
WATCH · TERMINATED
Malaria, Falciparum
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN
SOURCE FACT Interim analysis showed more LCFs in one of the treatment arms
Rescueability · inferenceUNKNOWN
Current controlUNKNOWN
Next truth · USD / monthsUNKNOWN / UNKNOWN
Restart · inferenceUNKNOWN
Why this survived: Source-backed stopping context warrants a review, not qualification.
Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.
Principal risk: Transferable rights and decision-quality human evidence remain unresolved.
Investigate opportunitySource, stopping context and uncertainty
Interim analysis showed more LCFs in one of the treatment arms
Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established
Acquisition range: UNKNOWN · Market Pull: UNKNOWN
Confidence UNKNOWN. Source update 2007-11-27. Registry source
WATCH · TERMINATED
Malaria, Falciparum
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN
SOURCE FACT Interim analysis showed more LCFs in one of the treatment arms
Rescueability · inferenceUNKNOWN
Current controlUNKNOWN
Next truth · USD / monthsUNKNOWN / UNKNOWN
Restart · inferenceUNKNOWN
Why this survived: Source-backed stopping context warrants a review, not qualification.
Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.
Principal risk: Transferable rights and decision-quality human evidence remain unresolved.
Investigate opportunitySource, stopping context and uncertainty
Interim analysis showed more LCFs in one of the treatment arms
Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established
Acquisition range: UNKNOWN · Market Pull: UNKNOWN
Confidence UNKNOWN. Source update 2007-11-27. Registry source
WATCH · WITHDRAWN
Liver Transplant Failure and Rejection
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN
SOURCE FACT Staffing patterns
Rescueability · inferenceUNKNOWN
Current controlUNKNOWN
Next truth · USD / monthsUNKNOWN / UNKNOWN
Restart · inferenceUNKNOWN
Why this survived: Source-backed stopping context warrants a review, not qualification.
Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.
Principal risk: Transferable rights and decision-quality human evidence remain unresolved.
Investigate opportunitySource, stopping context and uncertainty
Staffing patterns
Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established
Acquisition range: UNKNOWN · Market Pull: UNKNOWN
Confidence UNKNOWN. Source update 2026-09-18. Registry source
WATCH · TERMINATED
Healthy Volunteers, Sjögren's Syndrome
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN
SOURCE FACT Company's strategic decision
Rescueability · inferenceUNKNOWN
Current controlUNKNOWN
Next truth · USD / monthsUNKNOWN / UNKNOWN
Restart · inferenceUNKNOWN
Why this survived: Source-backed stopping context warrants a review, not qualification.
Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.
Principal risk: Transferable rights and decision-quality human evidence remain unresolved.
Investigate opportunitySource, stopping context and uncertainty
Company's strategic decision
Why stranded: Corporate/strategic failure · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established
Acquisition range: UNKNOWN · Market Pull: UNKNOWN
Confidence UNKNOWN. Source update 2026-09-14. Registry source
WATCH · TERMINATED
Acute Lymphoblastic Leukemia
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN
SOURCE FACT Terminated by IRB for continuing review
Rescueability · inferenceUNKNOWN
Current controlUNKNOWN
Next truth · USD / monthsUNKNOWN / UNKNOWN
Restart · inferenceUNKNOWN
Why this survived: Source-backed stopping context warrants a review, not qualification.
Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.
Principal risk: Transferable rights and decision-quality human evidence remain unresolved.
Investigate opportunitySource, stopping context and uncertainty
Terminated by IRB for continuing review
Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established
Acquisition range: UNKNOWN · Market Pull: UNKNOWN
Confidence UNKNOWN. Source update 2007-12-28. Registry source
WATCH · TERMINATED
Acute Lymphoblastic Leukemia
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN
SOURCE FACT Terminated by IRB for continuing review
Rescueability · inferenceUNKNOWN
Current controlUNKNOWN
Next truth · USD / monthsUNKNOWN / UNKNOWN
Restart · inferenceUNKNOWN
Why this survived: Source-backed stopping context warrants a review, not qualification.
Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.
Principal risk: Transferable rights and decision-quality human evidence remain unresolved.
Investigate opportunitySource, stopping context and uncertainty
Terminated by IRB for continuing review
Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established
Acquisition range: UNKNOWN · Market Pull: UNKNOWN
Confidence UNKNOWN. Source update 2007-12-28. Registry source